Cargando…
Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases
Brain metastases from non-medullary thyroid carcinoma (NMTC) are rare, with a reported frequency of ~1%, and patient survival time is <1 year after diagnosis. The optimal management of brain metastases in this setting continues to be debated. The aim of the present study was to evaluate a series...
Autores principales: | Slutzky-Shraga, Ilana, Gorshtein, Alex, Popovitzer, Aharon, Robenshtok, Eyal, Tsvetov, Gloria, Akirov, Amit, Hirsch, Dania, Benbassat, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768058/ https://www.ncbi.nlm.nih.gov/pubmed/29387239 http://dx.doi.org/10.3892/ol.2017.7325 |
Ejemplares similares
-
THU087 Natural History Of Nonfunctioning Pituitary Macroadenomas Followed Without Intervention
por: Ayalon-Dangur, Irit, et al.
Publicado: (2023) -
Total versus hemithyroidectomy for small unilateral papillary thyroid carcinoma
por: HIRSCH, DANIA, et al.
Publicado: (2014) -
Familial non-medullary thyroid cancer: a critical review
por: Capezzone, M., et al.
Publicado: (2020) -
Clinical characteristics of a large familial cohort with Medullary thyroid cancer and germline Cys618Arg RET mutation in an Israeli multicenter study
por: Rosenblum, Rachel Chava, et al.
Publicado: (2023) -
Clinical Study and Systematic Review of Pituitary Microadenomas vs. Macroadenomas in Cushing’s Disease: Does Size Matter?
por: Akirov, Amit, et al.
Publicado: (2022)